Treatments used in patients with AIIRD
| AIIRD diagnosis, n | Immunosuppressive treatments, n (%) | ||||||||
| GC | MTX | TNFi | IL6i | Anti-CD20 | ABA | JAKi | IL17i | MMF | |
| All AIIRD, n=686 | 130 (18.95) | 176 (25.66) | 172 (25.07) | 37 (5.39) | 87 (12.68) | 16 (2.33) | 49 (6.9) | 48 (7) | 28 (4.08) |
| RA, n=263 | 55 (20.91) | 116 (44.11) | 47 (17.87) | 29 (11.03) | 43 (16.35) | 15 (5.7) | 46 (16.9) | 0 | 0 |
| PsA, n=165 | 3 (1.82) | 36 (21.82) | 74 (44.85) | 0 | 0 | 1 (0.61) | 2 (1.2) | 40 (24.24) | 0 |
| AxSpA, n=68 | 1 (1.47) | 9 (13.24) | 48 (70.59) | 0 | 1 (1.47)* | 0 | 0 | 8 (11.76) | 2 (2.94) |
| SLE, n=101 | 22 (21.78) | 8 (7.92) | 0 | 0 | 7 (6.93) | 0 | 0 | 0 | 17 (16.83) |
| IIM, n=19 | 15 (78.95) | 2 (10.53) | 0 | 0 | 13 (68.42) | 0 | 0 | 0 | 6 (31.58) |
| LVV, n=21 | 11 (52.38) | 2 (9.52) | 1 (4.76) | 8 (38.1) | 0 | 0 | 0 | 0 | 0 |
| AAV, n=26 | 12 (46.15) | 2 (7.69) | 0 | 0 | 18 (69.23) | 0 | 0 | 0 | 0 |
| Other vasculitis, n=23 | 11 (47.83) | 1 (4.35) | 2 (8.7) | 0 | 5 (21.74) | 0 | 0 | 0 | 3 (13.04) |
*This patient had multiple sclerosis and was treated with ocrelizumab.
AAV, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; ABA, abatacept; AIIRD, autoimmune inflammatory rheumatic diseases; anti-CD20, CD-20 inhibitors; AxSpA, axial spondyloarthritis; GC, glucocorticoids; IIM, idiopathic inflammatory myositis; IL6i, interleukin 6 inhibitors; IL17i, interleukin 17 inhibitors; JAKi, Janus kinase inhibitors; LVV, large vessel vasculitis; MMF, mycophenolate mofetil; MTX, methotrexate; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TNFi, tumour necrosis factor inhibitors.